10 May 2022 , 01:28 AM
For the full year FY22, the revenues were higher by 15.5% at Rs2,489 crore. For Q4FY22, API revenues grew by 46% while API volumes grew by 23%. On a yoy basis, the formulations revenues grew 7.8% while the specialty chemicals revenues grew by 17%.
It expects the growth trajectory of the active pharma ingredients (APIs) to gather momentum in the coming quarters. Exports contributed 39% of the formulation revenues.
The reason for the fall in profits was the sharp spike in raw material costs. EBITDA for Q4FY22 was up 9.1% at Rs89 crore while EBITDA margins tapered by 351 basis points to 12.8% in the Q4FY22 quarter from 16.35 in the Q4FY21 quarter.
Net margins stood at 7.97% in Q4FY22 quarter compared to 10.29% in Q4FY21. NPM was lower sequentially against 9.18% in Q3FY22. Net cash flows got impacted by spike in receivables.
Financial highlights for Mar-22 compared yoy and sequentially
Aarti Drugs | |||||
Rs in Crore | Mar-22 | Mar-21 | YOY | Dec-21 | QOQ |
Total Income (Rs cr) | ₹ 694.27 | ₹ 501.75 | 38.37% | ₹ 634.80 | 9.37% |
Net Profit (Rs cr) | ₹ 55.34 | ₹ 51.65 | 7.14% | ₹ 58.29 | -5.06% |
Diluted EPS (Rs) | ₹ 5.97 | ₹ 5.54 | ₹ 6.29 | ||
Net Margins | 7.97% | 10.29% | 9.18% |
Related Tags
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.